Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents.


Journal

Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637

Informations de publication

Date de publication:
25 09 2019
Historique:
received: 08 07 2019
accepted: 17 09 2019
entrez: 27 9 2019
pubmed: 27 9 2019
medline: 12 5 2020
Statut: epublish

Résumé

Gene coding mutations found in sodium glucose co-transporters (SGLTs) are known to cause renal glucosuria. SGLT2 inhibitors have recently been shown to be effective hypoglycemic agents as well as possessing cardiovascular and renal protective properties. These beneficial effects have to some extent, been attributed to weight loss and reduced blood pressure. The aim of the current study was to evaluate the prevalence of renal glucosuria amongst a large cohort of Israeli adolescents and to investigate whether renal glucosuria is associated with lower body weight and lower blood pressure values. Medical and socio-demographic data were collected from the Israeli Defense Force's conscription center's database. A cross-sectional study to evaluate the association between conscripts diagnosed as overweight [BMI percentiles of ≥ 85 and < 95 and obesity (≥ 95 BMI percentile)] and afflicted with renal glucosuria was conducted. In addition, we assessed the association of renal glucosuria with elevated diastolic and systolic blood pressure. Multinomial regression models were used. The final study cohort comprised 2,506,830 conscripts of whom 1108 (0.044%) were diagnosed with renal glucosuria, unrelated to diabetes mellitus, with males twice as affected compared to females. The adjusted odds ratio for overweight and obesity was 0.66 (95% CI 0.50-0.87) and 0.62 (95% CI 0.43-0.88), respectively. Adolescents afflicted with renal glucosuria were also less likely to have an elevated systolic blood pressure of 130-139 mmHg with an adjusted odds ratio of 0.74 (95% CI 0.60-0.90). Renal glucosuria is associated with lower body weight and obesity as well as with lower rates of elevated systolic blood pressure.

Sections du résumé

BACKGROUND
Gene coding mutations found in sodium glucose co-transporters (SGLTs) are known to cause renal glucosuria. SGLT2 inhibitors have recently been shown to be effective hypoglycemic agents as well as possessing cardiovascular and renal protective properties. These beneficial effects have to some extent, been attributed to weight loss and reduced blood pressure. The aim of the current study was to evaluate the prevalence of renal glucosuria amongst a large cohort of Israeli adolescents and to investigate whether renal glucosuria is associated with lower body weight and lower blood pressure values.
METHODS
Medical and socio-demographic data were collected from the Israeli Defense Force's conscription center's database. A cross-sectional study to evaluate the association between conscripts diagnosed as overweight [BMI percentiles of ≥ 85 and < 95 and obesity (≥ 95 BMI percentile)] and afflicted with renal glucosuria was conducted. In addition, we assessed the association of renal glucosuria with elevated diastolic and systolic blood pressure. Multinomial regression models were used.
RESULTS
The final study cohort comprised 2,506,830 conscripts of whom 1108 (0.044%) were diagnosed with renal glucosuria, unrelated to diabetes mellitus, with males twice as affected compared to females. The adjusted odds ratio for overweight and obesity was 0.66 (95% CI 0.50-0.87) and 0.62 (95% CI 0.43-0.88), respectively. Adolescents afflicted with renal glucosuria were also less likely to have an elevated systolic blood pressure of 130-139 mmHg with an adjusted odds ratio of 0.74 (95% CI 0.60-0.90).
CONCLUSIONS
Renal glucosuria is associated with lower body weight and obesity as well as with lower rates of elevated systolic blood pressure.

Identifiants

pubmed: 31554505
doi: 10.1186/s12933-019-0929-7
pii: 10.1186/s12933-019-0929-7
pmc: PMC6760097
doi:

Substances chimiques

SLC5A2 protein, human 0
Sodium-Glucose Transporter 2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

124

Références

Cardiovasc Diabetol. 2017 Jan 6;16(1):3
pubmed: 28056987
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Diabetes Care. 2016 May;39(5):717-25
pubmed: 27208375
J Korean Med Sci. 2017 Jun;32(6):985-991
pubmed: 28480657
Diabetes Care. 2010 Oct;33(10):2217-24
pubmed: 20566676
Clin Exp Nephrol. 2018 Aug;22(4):850-859
pubmed: 29330695
Diabetes Obes Metab. 2014 Feb;16(2):147-58
pubmed: 23906415
Diabetes Care. 2009 Apr;32(4):650-7
pubmed: 19114612
Diabetes Obes Metab. 2012 Jan;14(1):5-14
pubmed: 21955459
J Biomed Sci. 2017 Aug 31;24(1):64
pubmed: 28854935
J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31
pubmed: 22238392
Ann Intern Med. 2012 Mar 20;156(6):405-15
pubmed: 22431673
Clin J Am Soc Nephrol. 2010 Jan;5(1):133-41
pubmed: 19965550
Nat Rev Nephrol. 2017 Jan;13(1):11-26
pubmed: 27941935
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Diabetes Care. 2011 Sep;34(9):2015-22
pubmed: 21816980
J Inherit Metab Dis. 2000 May;23(3):237-46
pubmed: 10863940
Cardiovasc Diabetol. 2019 Apr 5;18(1):46
pubmed: 30953516
Adv Data. 2000 Jun 8;(314):1-27
pubmed: 11183293
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Pediatr Nephrol. 2012 Jul;27(7):1091-5
pubmed: 22314875
Diabetes Metab. 2014 Dec;40(6 Suppl 1):S17-22
pubmed: 25554067
Life Sci. 2005 Jan 14;76(9):1039-50
pubmed: 15607332
Am J Kidney Dis. 2009 May;53(5):875-83
pubmed: 19324482
Diabetes Care. 2014 Jul;37(7):1815-23
pubmed: 24929430
Am J Hypertens. 1999 Feb;12(2 Pt 1):223-6
pubmed: 10090352
Cardiovasc Diabetol. 2017 Feb 27;16(1):29
pubmed: 28241822
J Intern Med. 2007 Jan;261(1):32-43
pubmed: 17222166
Cardiovasc Diabetol. 2017 May 16;16(1):65
pubmed: 28511711
Lancet. 2013 Sep 14;382(9896):941-50
pubmed: 23850055
J Am Soc Hypertens. 2014 Apr;8(4):262-75.e9
pubmed: 24602971
Postgrad Med. 2016 May;128(4):371-80
pubmed: 27002421
Pediatr Int. 2018 Jan;60(1):35-40
pubmed: 29110414
Cardiovasc Diabetol. 2019 Aug 5;18(1):99
pubmed: 31382965

Auteurs

Boris Fishman (B)

Israel Defense Forces, Medical Corps, Tel Hashomer, Ramat Gan, Israel.
Internal Medicine D and Hypertension Unit, Sheba Medical Center, 2 Derech Sheba, Migdal Ishpuz, 1st Floor, Tel Hashomer, 5265601, Ramat Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.

Gadi Shlomai (G)

Internal Medicine D and Hypertension Unit, Sheba Medical Center, 2 Derech Sheba, Migdal Ishpuz, 1st Floor, Tel Hashomer, 5265601, Ramat Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.
The Institute of Endocrinology, Sheba Medical Center, Tel Hashomer, 5265601, Ramat Gan, Israel.

Gilad Twig (G)

Israel Defense Forces, Medical Corps, Tel Hashomer, Ramat Gan, Israel.
Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.
Department of Military Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Estela Derazne (E)

Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.

Alexander Tenenbaum (A)

Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.
Cardiac Rehabilitation Institute, Sheba Medical Center, Tel Hashomer, 5265601, Ramat Gan, Israel.

Enrique Z Fisman (EZ)

Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.

Adi Leiba (A)

Israel Defense Forces, Medical Corps, Tel Hashomer, Ramat Gan, Israel.
Division of Nephrology and Hypertension, Assuta Ashdod Academic Medical Center, 7747629, Ashdod, Israel.
Faculty of Health sciences, Ben Gurion University, Beer Sheva, Israel.
Department of Medicine, Mount Auburn Hospital, 330 Mt Auburn St, Cambridge, MA, 02138, USA.
Department of Medicine, Harvard Medical School, Boston, USA.

Ehud Grossman (E)

Internal Medicine D and Hypertension Unit, Sheba Medical Center, 2 Derech Sheba, Migdal Ishpuz, 1st Floor, Tel Hashomer, 5265601, Ramat Gan, Israel. grosse@tauex.tau.ac.il.
Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel. grosse@tauex.tau.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH